BCL2L1 and central nervous system cancer: Likewise, HCMV IE86 has been shown to impede apoptotic pathways in glioma cells through promoting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1)-mediated alternative splicing of Bcl-x, resulting in reduced Bcl-xS/Bcl-xL ratio (38).